Developing a vaccine to fight KSHV infection in nonhuman primates
Targeting CD180 to induce anti-KSHV response in nonhuman primates
['FUNDING_U01'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-11003457
This study is testing two different vaccine methods to see which one helps the immune system fight off the virus that causes Kaposi's Sarcoma, using nonhuman primates to find the best option for future vaccines.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-11003457 on ClinicalTrials.gov |
What this research studies
This research aims to explore two potential targets for a vaccine against Kaposi's Sarcoma-associated Herpesvirus (KSHV) in nonhuman primates. It will evaluate the effectiveness of two different vaccine strategies: one using mRNA-lipid nanoparticles, which have shown success in other vaccines, and another that targets CD180, a receptor that can enhance immune responses. By using a model that mimics KSHV infection, the researchers hope to determine which approach generates a stronger immune response and offers better protection against the virus.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at high risk for KSHV infection or those with compromised immune systems.
Not a fit: Patients who are not at risk for KSHV infection or those who do not have immune system challenges may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that effectively protects against KSHV, potentially reducing the incidence of related cancers in humans.
How similar studies have performed: Previous research has shown promise in using mRNA vaccines and targeting immune receptors like CD180, indicating potential for success in this novel approach.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WONG, SCOTT W — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: WONG, SCOTT W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: AIDS associated cancer, AIDS related cancer, Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome